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Objective: Within the interleukin-1 (IL-1) cytokine family, IL-1 receptor antagonist (IL1RN) gene variants
have been associated with radiological severity of knee osteoarthritis (OA) in cross-sectional studies. The
present study tested the relation between IL1RN gene variants and progression of knee OA assessed
radiographically by change in KellgreneLawrence (KL) score over time.
Design: 1153 Caucasian adults (age range: 44e89) from the Johnson County Osteoarthritis Project were
evaluated for unequivocal radiographic evidence of knee OA at baseline, deﬁned as KL score2, and were
re-examined after 4e11 years for radiographic changes typical of OA progression. IL1RN gene variants
were tested for association with OA progression and for potential interaction with body mass index
(BMI). Other IL-1 gene variations were tested for association with OA progression as a secondary
objective.
Results: Of 154 subjects with OA at baseline, 88 showed progression at follow-up. Seven IL1RN single
nucleotide polymorphisms (SNPs) and one IL-1 receptor SNP were associated with progression. Four
IL1RN haplotypes, each occurring in >5% of this population, showed different relationships with pro-
gression, including one (rs315931/rs4251961/rs2637988/rs3181052/rs1794066/rs419598/rs380092/
rs579543/rs315952/rs9005/rs315943/rs1374281; ACAGATACTGCC) associated with increased progres-
sion [odds ratio (OR) 1.91 (95%CI 1.16e3.15); P ¼ 0.012]. Haplotypes associated with progression by KL
score were also associated with categorical change in joint space narrowing. BMI was associated with OA
progression in subjects carrying a speciﬁc IL1RN haplotype, but not in subjects without that haplotype.
Conclusion: A signiﬁcantly greater likelihood of radiological progression of knee OAwas associated with a
commonly occurring IL1RN haplotype that could be tagged by three IL1RN SNPs (rs419598, rs9005,
rs315943). Interactions were also observed between IL1RN gene variants and BMI relative to OA pro-
gression. This suggests that IL1RN gene markers may be useful in stratifying patients for medical man-
agement and drug development.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Arthritis is one of the leading causes of disability1 and osteoar-
thritis (OA), the most common type, affects an estimated 27 million
people in the United States2. The knee is among the most usual
joints affected and was responsible for 686,000 total knee: K.S. Kornman, Interleukin
. Tel: 1-617-480-8332.
), vkondragunta@gmail.com
Kornman), hwayingwang@
G.W. Duff), Jordan_renner@
du (J.M. Jordan).
s Research Society International. Preplacements (TKR) in 2009, a cumulative growth of 84% from 1997,
making TKR the 14th most common hospital procedure in 20093.
There is inter-individual variation in the rate of progression of
knee OA, but factors determining progression are poorly under-
stood. Inability to predict which patients with knee OA are likely to
exhibit measurable disease progression during a monitoring period
has added to the difﬁculty of developing disease-modifying
interventions.
Although twin and family studies point to a signiﬁcant genetic
component4e7, few gene variants implicated in OA susceptibility or
pathogenesis have been replicated independently or proven robust
in meta-analyses. The majority of OA genetic studies have focused
on disease susceptibility, and phenotype diversity has complicatedublished by Elsevier Ltd. All rights reserved.
X. Wu et al. / Osteoarthritis and Cartilage 21 (2013) 930e938 931attempts to synthesize published ﬁndings8. Few studies have
evaluated the genetics of OA progression5,9e13. Availability of a
longitudinally monitored population cohort provides a reduction in
selection biases that may enrich caseecontrol studies for more
complex phenotypes and the opportunity to explore risk factors
that differentiate progressive disease at a stage when intervention
may be more successful.
The Interleukin-1 (IL-1) family of cytokines has been implicated
in the pathogenesis of OA (notably agonist IL-1b and the receptor
antagonist IL-1Ra), and several IL-1 gene variants have been asso-
ciated with various OA phenotypes, but meta-analyses have not
supported a role for the IL-1 gene family in susceptibility to knee
OA14,15. Our present study was not concerned with susceptibility to
OA, but aimed to detect any relation of IL-1 receptor antagonist gene
(IL1RN) variants with the progression of established OA of the knee.
Speciﬁc haplotypes of IL1RN have previously been associated with
radiographic severity of symptomatic knee OA in clinic pop-
ulations16. The current study used awell-deﬁned population cohort
sample fromthe JohnstonCountyOsteoarthritis Project to test IL1RN
polymorphisms in relation to radiographic progression of knee OA
over 4e11 years. In addition, other variations in the IL-1 gene cluster
were evaluated for their potential link with OA progression.
Materials and methods
Study subjects and radiographic assessments
This study examined radiographic progression of knee OA using
data from the Johnston County (JoCo) Osteoarthritis Project, a
population-based study of OA in Johnston County, NC, USA. Insti-
tutional Review Boards of the Centers for Disease Control and
Prevention and the University of North Carolina School of Medicine
approved the protocol, and all subjects provided written consent
for analysis of genetic and non-genetic biomarkers.
Details of the population cohort study have been reported
previously17. The JoCo study was designed to be representative of
the civilian, non-institutionalized English-speaking black and
white population age 45 years. Baseline examination of subjects
was conducted between 1990 and 1997, and subjects were re-
examined 4e11 years later. Anterioreposterior standing knee ra-
diographs were obtained with footmat positioning at both time
points and read by a single musculoskeletal radiologist for
KellgreneLawrence score (KL, 0e4)18. KL scores are the most
commonly used measures in population-based studies of radio-
graphic knee OA19. A KL score of 2 indicates at least mild
radiographic OA20. X-rays were also evaluated for presence and
severity of joint space narrowing (JSN), scored 0e3 (0 ¼ none,
1 ¼mild or >0 and up to 33% JSN, 2 ¼moderate or >33% and up to
66% JSN, and 3 ¼ severe or from >66 to 100% JSN), using the
Burnett atlas21. Demographic and clinical characteristics, such as
sex, race, education, history of knee injury, and presence of knee
symptoms, were assessed in an interviewer-administered ques-
tionnaire. A total of 3187 and 1733 eligible subjects completed
both home interviews and clinical examinations at baseline and
ﬁrst follow-up, respectively.
All Caucasian subjects in the JoCo cohort were selected for in-
clusion if they completed clinical examinations and home in-
terviews at both baseline and follow-up, and had blood samples
available for DNA extraction. These included a total of 1172 subjects,
of which 19were excluded prior to analysis because of questionable
gender or ethnicity designations.
All subjects who had radiographic knee OA at baseline (KL  2)
were divided into either progressors (cases) or non-progressors
(controls). Progressors had an increase in KL score at follow-up,
whereas non-progressors did not.Genetic variations
We analyzed 21 single nucleotide polymorphisms (SNPs): two
SNPs in IL-1a (IL1A) gene, six SNPs in IL-1b (IL1B) gene, one SNP in
the IL1R1 gene, and 12 SNPs in the IL-1 receptor antagonist (IL1RN)
gene on chromosome 2q13 (Table I). The 12 assayed IL1RN SNPs
included seven IL1RN gene tag SNPs that capture (r2 > 0.80) 94% of
the Caucasian European HapMap SNPs with minor allele frequency
>5% (HapMap release 24, CEU population)22 and an additional ﬁve
IL1RN SNPs that have been reported in the OA literature.
Genotyping
All genotyping were performed in a clinical genetics laboratory
(Interleukin Genetics; Waltham, MA) that has been certiﬁed to
United States federal regulatory standards (Clinical Laboratory
Improvement Amendments 1988 (CLIA)). DNA was extracted from
blood samples using standard protocols. Before polymerase chain
reactions (PCR), DNAwas diluted to adjust concentrations towithin
a range compatible with multiplex PCR conditions. SNP genotyping
was performed by the single-base extension (SBE) method using
the SNPstream instrument and chemistry (Beckman Coulter; Brea,
CA) with SNPsmultiplexed as needed to avoid interference. The SBE
reaction was performed as per manufacturer’s protocol, and “tag-
ged” products were hybridized to a 48-plex microarray plate. Plates
were read by the SNPstream instrument and SNPstream software
determined initial allele calls, which were conﬁrmed by a tech-
nologist. We validated the assay accuracy and reproducibility of
genotyping assays for all SNPs prior to genotyping all study sam-
ples. Each validation plate (384 wells) included negative controls
(water, n ¼ 10), positive controls of known genotypes (Coriell,
n ¼ 16), and a subset of study samples (n ¼ 110). Positive controls
and study samples were genotyped in duplicate or triplicate.
Statistical methods
Genotyping performance was assessed as total genotyping suc-
cess rate, genotype concordance rate between duplicates, and
HardyeWeinberg Equilibrium (HWE). SNPs with minor allele fre-
quencies<0.01 were excluded. Extent of linkage disequilibrium (LD)
was assessed as r2 using Haploview23 version 3.3. Logistic regression
analysis24 was applied to examine association between SNP variants
and OA progression (increase in KL score from baseline to follow-up).
Nonparametric WilcoxoneManneWhitney test25,26 was used to
compareOAprogression rates between subjectswithhighbodymass
index (BMI) (>median) and subjects with low BMI (median).
A backward elimination method27 was used to identify the most
efﬁcient set of tag SNPs for IL1RN haplotypes associated with OA
progression. The 12 IL1RN SNPs were used to produce the ﬁrst
haplotype model. Then each of the 12 SNPs was removed to create
12 11-SNP models. Of these, the one with the lowest associated
P value was deemed the best model. Each SNP was removed from
this best 11-SNP model to create 11 10-SNP models. Again, the one
with the lowest P valuewas considered the best 10-SNPmodel. This
process was repeated to identify the best 9-SNP, 8-SNP, 7-SNP, 6-
SNP, 5-SNP, 4-SNP, 3-SNP, 2-SNP and 1-SNP models. For each
model, we used Haplo.stat28 to estimate haplotype frequencies for
cases and controls and to estimate an odds ratio (OR) for each in-
dividual haplotype to determine whether haplotypes differed
signiﬁcantly between cases and controls. Overall, 77 tests were
evaluated in the backward elimination models to determine which
had the lowest P value. Bonferroni correctionwas used to adjust for
multiple testing, and a speciﬁc model was considered signiﬁcant if
it had a P value<0.000649. Alternatively, false discovery rate29 was
used to correct multiple comparisons.
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X. Wu et al. / Osteoarthritis and Cartilage 21 (2013) 930e938932We used a conditional haplotype analysis30 (WHAP) to deter-
mine which of the 12 IL1RN SNPs were responsible for haplotype
association with progression observed in this sample. Statistical
software, including PLINK31, JMP genomics (SAS Institute Inc., Cary,
NC, 1989e2007.), and SAS (SAS Institute Inc., Cary, NC, 1989e2007),
were used in the analysis.
Results
Multiplexed genotyping assays for all of the IL-1 SNPs (Table I),
as described in the Methods section, were 100% accurate for sam-
ples of known genotypes, and averaged 99.5% concordance (range:
96.5e100.0%) between study sample replicates. Five of the 1153
samples had genotyping failure rates that exceeded quality assur-
ance standards and were excluded from the analysis, leaving 1148
samples with genotyping data for IL-1 SNPs. No major population
stratiﬁcation was detected in this cohort as assessed by genome-
wide association study (GWAS) data (data not shown). Pairwise
LD estimates (r2) were calculated for the IL1RN SNPs and are shown
in Supplemental Fig. 1.
Progression
1148 subjects with baseline and follow-up radiographs and ge-
netic data were classiﬁed as to presence (KL score of 2 for at least
one knee) or absence of knee OA at baseline. Characteristics of
study subjects are shown in Table II. Additional description of OA
progressors can be found in Supplemental Table I.
Of the 21 IL-1 gene variations analyzed as single SNPs, seven of
the 12 IL1RN SNPs assayed and one in the IL-1 receptor type 1 gene
(IL1R1) were signiﬁcantly associated with radiographic progression
of knee OA measured by change in KL score (Table III). No IL1A or
IL1B SNPs were associated with radiographic progression.
Haplotypes
The IL1RN 3-SNP (rs419598/rs315952/rs9005) haplotypes previ-
ously associated with knee OA severity16 were associated with
radiographic progression of knee OA in this population cohort
(P ¼ 0.0004; Table IV). Haplotype frequencies observed in this
JoCo cohort (n ¼ 1148) were similar to those reported for Utah resi-
dents with ancestry from northern and western Europe in the Hap-
Map database (HapMap release 28, CEU population)22. The CTA
haplotype, previously reported as protective in a cross-sectional
study of severity, was not associated with disease progression in the
present population cohort study (OR¼ 1.16; P¼ 0.613)16, whereas the
TTG haplotype was more frequent in progressors and the TCG and
TTA haplotypes were more frequent in non-progressors (Table IV).
Since multiple SNPs in the IL1RN gene were associated with
progression and the current study provided broad coverage of the
genetic variation in the gene, we constructed de novo haplotypes
using combinations of 12 IL1RN SNPs.
Of the nine 12-SNP IL1RN haplotypes observed in this popula-
tion at an estimated frequency of 1%, four were at 5% (Table V).
Subjects with genetic markers contained in haplotype pattern 1
had an increased likelihood of progression and subjects with
pattern 3 appeared to be protected from progression during the
follow-up period. Using the Relative Predispositional Effect anal-
ysis32, pattern 1 was shown to confer the largest effect on disease
progression while pattern 3 had no effect (Supplemental Table II).
These analyses indicate that one common haplotype (pattern #1)
was associated with radiographic progression of the knee.
To determine which combinations of SNPs most efﬁciently
captured the disease related information in the 12-SNP IL1RN
haplotypes, we used a backward elimination method, as described
Table II
Characteristics of study subjects
Total cohort
(n ¼ 1148)
Baseline
KL  2
(n ¼ 154)
Radiographic
progression
(n ¼ 88)
No radiographic
progression
(n ¼ 66)
Mean/freq
(SD)
Mean/freq
(SD)
Mean/freq
(SD)
Mean/freq
(SD)
Age 60.3 (9.5) 64.5 (10.6) 64.6 (10.6) 64.5 (10.6)
BMI 28.3 (5.2) 30.0 (6.3) 30.8 (6.5) 28.8 (5.9)
Gender (Male) 38% 35% 33% 38%
X. Wu et al. / Osteoarthritis and Cartilage 21 (2013) 930e938 933in the Methods section. Three SNPs (rs419598/rs9005/rs315943)
produced the only signiﬁcant model after correction for multiple
testing as shown in Table VI. Models composed of four or ﬁve SNPs
approached but did not reach signiﬁcance after correction, and no
other haplotype models approached signiﬁcance after correction
(full model in Supplemental Table III).
In the best 3-SNP model, one speciﬁc haplotype (TGC;
frequency ¼ 0.41) was signiﬁcantly associated with increased
risk of radiographic progression, two haplotypes (CAT,
frequency ¼ 0.26; TGT, frequency ¼ 0.28) had no inﬂuence on risk
for progression, and one haplotype (TAT, frequency ¼ 0.04) was
associated with decreased risk of radiographic progression
(Supplemental Table IV). We then estimated (HaploStat) fre-
quencies of 3-SNP (rs419598/rs9005/rs315943) IL1RN haplotypes in
radiographic progressors and non-progressors, as measured by
change in KL score and by categorical JSN scores (Table VII; KL
change P ¼ 0.0003; JSN change P ¼ 0.044). The haplotype (TGC),
which was associated with KL progression in the backward elimi-
nation model, was more frequent in KL progressors versus
non-progressors (P ¼ 0.006) and in JSN progressors versus non-
progressors (P ¼ 0.015). The TGC association with progression
remained signiﬁcant after adjustment for age, gender and BMI (KL
progression: OR ¼ 2.05, P ¼ 0.0059; JSN progression: OR ¼ 2.35,
P ¼ 0.0172). Two other haplotypes were more frequent in KL non-
progressors and showed similar, but non-signiﬁcant, directional
associations with JSN progression.
We examined the test performance parameters of the IL1RN
gene markers in predicting OA progression (Supplemental
Table IV). Depending on the genetic model (dominant or reces-
sive) used, sensitivity of the test ranged from 20.5% to 75%, speci-
ﬁcity from 49.2% to 87.7%, positive predictive value from 66.7% to
69.2%, and negative predictive value from 44.9% to 59.3%.
We also evaluated whether there was interaction between the
TGC haplotype and BMI, which has been strongly associated with
long-term progression of knee OA33. The rate of progression was
not signiﬁcantly higher in subjects with a BMI greater than the
median (28.5 kg/m2) compared to those below the median
(Supplemental Fig. 2). For subjects who did not carry the TGCTable III
SNPs associated with progression of radiographic knee OA: change of KL score in subjec
Gene SNP* Associated allele/Genotype Genetic model
IL1R1 rs2287047 T Dominant
IL1RN rs4251961 C Dominant
IL1RN rs2637988 A Dominant
IL1RN rs1794066 A Dominant
IL1RN RS380092 T Dominant
IL1RN RS315952 C Dominant
IL1RN rs315943 C Dominant
IL1RN rs1374281 C Dominant
LD (r2) between adjacent SNPs in the IL1RN gene: 0.38 for rs4251961 and rs2637988; 0.93
rs315952; 0.27 for rs315952 and rs315943; 0.86 for rs315943 and rs1374281.
* SNP Reference sequence number in database of SNPs (dbSNP)50.
y Logistic regression modeling for individual SNPs are shown with adjustments for aghaplotype, BMI did not inﬂuence the progression rate
(Supplemental Fig. 2; P ¼ 0.84) whereas elevated BMI increased
progression rate in TGC positive individuals (Supplemental Fig. 2;
P ¼ 0.04).
In addition to deﬁning a subset of SNPs that efﬁciently tag the
broad haplotypes associated with progression, we sought to
determine which SNPs may explain IL1RN genetic risk for pro-
gression. A conditional haplotype analysis30 was used to determine
which SNPs among the 12 were essential for the observed haplo-
type association with risk (Table VIII). Signiﬁcant haplotype asso-
ciations with progression were eliminated by conditioning the
model on any one of the ﬁve SNPs: rs4251961, rs380092, rs315952,
rs315943, and rs1374281, indicating each was essential to the
observed signiﬁcant haplotype associations with progression
(Table VIII).
Although no individual IL1A or IL1B SNP was signiﬁcantly
associated with radiographic progression in this cohort, some IL1B
SNPs (rs16944, rs1143623, rs4848306) have been reported to
function in haplotype context34 to inﬂuence clinical levels of IL-1b
and C-reactive protein35. We evaluated haplotypes for the eight
SNPs covering the IL1AeIL1B region and also for the three IL1B
promoter SNPs (rs16944, rs1143623, rs4848306). Of the 12 IL1Ae
IL1B haplotypes observed in>0.01 frequency, only one (TTGTGACG;
rs17561/rs10496444/rs1143643/rs1143634/rs1143633/rs16944/rs1
143623/rs4848306) of low frequency (0.024) was signiﬁcantly
associated with radiographic progression after adjustment for age,
gender, BMI (OR ¼ 0.09; P ¼ 0.0316). No IL1B promoter haplotypes
were associated with progression.Discussion
OA is a complex chronic disease of aging with initiation and
progression apparently inﬂuenced by multiple factors, including
genetics, body weight, trauma, dysplastic tissues and biome-
chanics33,36,37. In spite of practical challenges associated with dis-
ease heterogeneity, the ability to predict which OA patients are
more likely to exhibit measurable knee OA progression during a
deﬁned time period should advance the development of disease-
modifying drugs.
The primary objective of this study was to test whether IL1RN
gene variations previously associated cross-sectionally with knee
OA severity15,16,38 or susceptibility39,40 might be associated with
longitudinally monitored radiographic progression of knee OA in a
population cohort. We found a signiﬁcant association between
progression and several SNPs and their haplotypes in the gene for
IL-1Ra, indicating that variants of this gene may be important
predictive markers of severity or progression. Four 12-SNP IL1RN
haplotypes accounted for 88% of those observed at frequencies
>0.01 in the cohort and one commonly occurring 12-SNP haplotypets with baseline KL  2
OR 95%CI P valuey q value (false discovery rate)
2.34 1.16e4.74 0.018 0.075
3.06 1.49e6.26 0.002 0.016
2.97 1.17e7.49 0.021 0.075
3.58 1.40e9.16 0.008 0.041
0.44 0.22e0.87 0.019 0.389
0.49 0.25e0.97 0.039 0.415
3.06 1.50e6.23 0.002 0.016
3.11 1.53e6.31 0.002 0.016
for rs2637988 and rs1794066; 0 for rs1794066 and rs380092; 0.78 for rs380092 and
e, BMI, and gender.
Table IV
IL1RN haplotypes previously associated with knee OA severity were associated with OA progression
IL1RN SNPs in
haplotype
Haplotype Freq in JoCo
cohort*
Freq in
HapMapy
Freq in
progressors
Freq in non-
progressors
Unadjusted
P value
Adjusted
OR
Adjusted
P value
rs419598/rs315952/rs9005 TTG 0.42 0.42 0.47 0.32 0.0075 1.96 0.009
TCG 0.27 0.25 0.26 0.37 0.037 0.57 0.037
CTA 0.26 0.27 0.27 0.24 0.535 1.16 0.613
TTA 0.04 0.04 0.01 0.08 0.012 0.08 0.017
Omnibus 0.0004
* Caucasians in the Johnston County Osteoarthritis Project17; n ¼ 1148.
y HapMap (HapMap release 28, CEU population)22.
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(OR ¼ 1.91; P ¼ 0.012).
The 12-SNP IL1RN haplotypes associated with differential risk
for progression were efﬁciently tagged using three speciﬁc SNPs
(rs419598/rs9005/rs315943). However, multiple combinations of
three or more SNPs will identify the same set of extended haplo-
types, including the three SNPs (rs419598/rs315952/rs9005) pre-
viously reported to be associated with knee OA severity16.
To investigate which of the IL1RN SNPs examined in this study
contributed to the association with progression observed with the
12-SNP haplotypes, we used a conditional analysis that controlled
for each speciﬁc SNP. This was accomplished by comparing asso-
ciation with progression for 12-SNP haplotypes with the two
different alleles at each conditioning SNP. Loss of haplotype asso-
ciation with progression when conditioning on a speciﬁc SNP
indicated that the SNP contributed to the association signal,
compatible with a mechanistic role in the association for that
speciﬁc SNP or another in LD with it. With the conditional analysis,
only rs4251961, rs380092, rs315952, rs315943, and rs1374281
contributed to the observed associationwith progression. SNPs that
were identiﬁed by the backward elimination method were not
identical to those identiﬁed by conditional analysis to be important
for, or potentially causal to, disease progression. This observation is
not surprising since the best combination of SNPs that tag haplo-
types associated with a trait may not include all SNPs important or
causal to the trait. Presumably important/causal SNPs for OA pro-
gression identiﬁed in this study were highly linked, thus would
provide redundant information in tagging haplotypes associated
with disease progression and be eliminated in the analysis of the
best tagging SNPs.
Using two different analytical methods, SNPs in both LD blocks
(Supplemental Fig. 1) were shown to be associated with radio-
graphic progression of knee OA. This suggests that IL1RN gene or
another gene tagged by these IL1RN SNP markers may contribute to
the pathogenesis of OA or its progression. SNPs in LD block 1
(Supplemental Fig. 1) that best tagged the predominant haplotypes
(rs419598) or were identiﬁed in the conditional analysisTable V
IL1RN haplotypes and radiographic progression of knee OA: change of KL score
Pattern Haplotype* Frequency
All Progressor
1 ACAGATACTGCC 0.37 0.43
2 CTGGGCATTATG 0.22 0.21
3 ATAGATTCCGTG 0.13 0.09
4 ATGAGTTCCGTG 0.11 0.09
5 CTGAGTTCCGTG 0.04 0.05
6 ATAGATACTGCC 0.02 0.02
7 ATAGGCATTATG 0.02 0.03
8 CTAGATTCTATG 0.02 0.01
9 ACAGATACTGCG 0.01 0.01
* SNP order in haplotypes: rs315931/rs4251961/rs2637988/rs3181052/rs1794066/rs4(rs4251961) have been reported to have genotype-speciﬁc biolog-
ical activity. In a study of osteolysis after total hip arthroplasty,
allele C at rs419598 (a tag of haplotype #2; Table V), was associated
with reduced risk for osteolysis (OR ¼ 0.66; P ¼ 0.012)41; and
stimulated peripheral blood mononuclear cells from subjects with
rs419598 genotype CC had increased IL-1Ra mRNA expression
compared with genotype TT. In European and American Caucasian
populations, allele C of the promoter polymorphism rs4251961,
that tags IL1RN haplotype #1 (Table V), has been associated with
lower blood levels of IL-1Ra42,43, but the allele-speciﬁc effects on IL-
1Ra were reversed in sub-Saharan Africans44. The other LD block
includes two of the three haplotype tags (rs9005 and rs315943) and
two of the ﬁve SNPs identiﬁed in the conditional analysis (rs315943
and rs315952). Most of these SNPs are in the 30 untranslated region
of the IL1RN gene which has been reported to have a post-
transcriptional inﬂuence on IL-1Ra levels45.
In a previous report16 IL1RN haplotypes deﬁned by 3-SNPs
(rs419598/rs315952/rs9005) were associated with radiographic
severity of knee OA, with the CTA haplotype having lower fre-
quency in patients with severe knee OA (KL ¼ 3,4) than those with
less severe radiographic OA (KL ¼ 1,2). In the present study,
although the 3-SNP haplotypes deﬁned by rs419598, rs315952 and
rs9005 were differentially associated with progression (Table IV),
the speciﬁc CTA haplotype showed no relationship to knee OA
progression (OR ¼ 1.16; P ¼ 0.613). The CTA haplotype ﬁndings in
the two studies may be consistent given the prior report included
symptomatic patients from hospital rheumatology clinics with
radiographic knee OA, as opposed to the current population cohort
inwhich knee OAwas identiﬁed radiographically without regard to
symptoms. The haplotype frequencies observed in the JoCo cohort
(Table IV) were similar to those reported for European heritage
Caucasians in the HapMap database (HapMap release 28, CEU
population)22. In the population cohort, the differences in haplo-
type frequencies between the non-progressors and progressors
may be reasonably interpreted to represent biological differences
attributable to the haplotypes that inﬂuence the disease. In the
cross-sectional comparison of severity, the differences in haplotypeOR 95%CI P
Non-progressor
0.29 1.91 1.16e3.15 0.012
0.20 0.97 0.54e1.74 0.91
0.17 0.45 0.21e0.98 0.044
0.14 0.53 0.26e1.09 0.084
0.03 1.48 0.45e4.84 0.521
0.02 1.21 0.21e7.05 0.835
0.01 4.51 0.50e40.26 0.178
0.03 0.45 0.08e2.67 0.381
0.01 1.25 0.11e14.5 0.86
19598/rs380092/rs579543/rs315952/rs9005/rs315943/rs1374281.
Table VI
Best two to six SNP models relative to radiographic knee OA progression
Number of SNPs SNP order within haplotypes Haplotype Freq OR P value* q value (false
discovery rate)
6 RS3181052jRS179406
6jRS419598jRS315952
jRS9005jRS315943
GATTGC 0.41 1.96 0.0086 0.0432
GGCTAT 0.26 1.16 0.6130 0.6130
GATTAT 0.04 0.08 0.0233 0.0583
AGTCGT 0.12 0.65 0.1610 0.2150
GATCGT 0.15 0.6 0.1720 0.2150
Omnibus P value ¼ 0.001066
5 RS3181052jRS179406
6jRS419598jRS9005jR
S315943
GATGC 0.41 2.04 0.0061 0.0304
GGCAT 0.26 1.16 0.6130 0.6130
GATAT 0.04 0.09 0.0232 0.0580
AGTGT 0.12 0.65 0.1610 0.2163
GATGT 0.15 0.6 0.1730 0.2163
Omnibus P value ¼ 0.0009193
4 RS3181052jRS419598j
RS9005jRS315943
GTGC 0.41 2.04 0.0059 0.0297
GCAT 0.26 1.16 0.6130 0.6130
GTAT 0.04 0.08 0.0233 0.0583
ATGT 0.12 0.66 0.1850 0.2313
GTGT 0.15 0.55 0.1240 0.2067
Omnibus P value ¼ 0.0008631
3 RS419598jRS9005jRS315943 TGC 0.41 2.05 0.0059 0.0235
CAT 0.26 1.16 0.6130 0.6130
TAT 0.04 0.09 0.0233 0.0466
TGT 0.28 0.57 0.0355 0.0473
Omnibus P value ¼ 0.0003149
2 RS419598jRS315943 TC 0.42 2.04 0.0061 0.0091
CT 0.27 1.11 0.7350 0.7350
TT 0.31 0.44 0.0019 0.0058
Omnibus P value ¼ 0.002012
* Adjusted for age, gender and BMI.
X. Wu et al. / Osteoarthritis and Cartilage 21 (2013) 930e938 935frequencies may be a function of both biological differences directly
related to severity as well as depletion/enrichment effects of se-
lection bias in a symptomatic clinic population. If the CTA haplo-
type has a neutral biological effect on progression, it may well be
depleted in a population that presents with symptomatic disease.
Of interest was the observed interaction between the IL1RN
gene variations and BMI, such that the BMI association with pro-
gression was only evident in subjects who carried the TGC haplo-
type (rs419598/rs9005/rs315943). This observation must be
explored in larger populations, but if validated represents a
reﬁnement of our understanding of mechanisms involved in body
weight inﬂuences on joint tissues.
In addition to haplotypes and single SNPs in the gene for IL-1Ra,
an SNP in the gene for the IL-1 type 1 receptor (IL1R1) was the only
other IL-1 family SNP associated with progression. IL-1a and IL-1b
agonists both bind IL-1R1 to initiate receptor signaling and IL-1
biologic activities, and IL-1Ra blocks activity by competitively bind-
ing the IL-1R1 siteswithout initiating signal transduction. Variations
in the regulatory region of IL1R1 have been associated with plasma
IL-1R1 levels46, and the IL1R1 SNP associatedwith progression in this
cohort was previously associated with severe hand OA47.
The current study has the strengths of awell-deﬁned phenotype
of radiographic progression of knee OA in a longitudinallyTable VII
Frequencies of the 3-SNP (rs419598/rs9005/rs315943) IL1RN haplotypes in radiograph
categorical JSN scores
Haplotype rs419598/
rs9005/rs315943
Freq in KL
progressors
Freq in KL non-
progressors
Una
P va
CAT 0.28 0.24 0.53
TGC 0.48 0.32 0.00
TGT 0.25 0.36 0.04
TAT 0.01 0.08 0.01
Omnibus 0.00monitored population cohort of Caucasians. The challenges of
deﬁning OA and its heterogeneity, and potential implications of not
doing so, have been discussed recently and are likely especially
important for genetic studies8,48. To assess the potential distinc-
tions between the genetics of progression and susceptibility in the
current cohort, we compared 396 control subjects for which both
knees had a KL ¼ 0 to 359 cases with a KL  2 for at least one knee
or knee replacement. Subjects with a maximum KL ¼ 1 at one or
both knees were excluded from analysis. It is of interest that when
subjects who were classiﬁed as having radiographic knee OA were
compared with those without knee OA, none of the 12 IL1RN SNPs
were signiﬁcantly associated with OA susceptibility in this popu-
lation (data not shown).
Few studies have evaluated the genetics of OA progression5,9e13.
Advantages of a longitudinally monitored population cohort
include a reduction in selection biases that may enrich casee
control studies for more complex phenotypes, and the opportunity
to explore risk factors that differentiate progressive disease at a
stage when intervention may be more successful. By limiting the
population to Caucasians, we reduced the variation in haplotype
frequencies among ethnicities that may complicate data in-
terpretations due to inadvertent enrichment of cases or controls.
IL1RN haplotype frequencies observed in the current study wereic progressors and non-progressors, as measured by change in KL score and by
djusted
lue
Freq in JSN
progressors
Freq in JSN non-
progressors
Unadjusted
P value
4 0.27 0.30 0.74
6 0.48 0.30 0.015
1 0.24 0.36 0.088
7 0.01 0.05 0.12
03 0.044
Table VIII
Conditional analysis of IL1RN haplotypes
P value
12-SNP haplotype omnibus model 0.023
SNP conditioned P value after SNP conditioning*
RS315931 0.009
RS4251961 0.245
RS2637988 0.017
RS3181052 0.021
RS1794066 0.017
RS419598 0.009
RS380092 0.250
RS579543 0.009
RS315952 0.250
RS9005 0.009
RS315943 0.245
RS1374281 0.245
* P value for haplotype association with progression after conditioning of the
single indicated SNP in the model.
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Map release 28, CEU population)22. The use of categorical radio-
graphic parameters to assess disease progression has some
limitations, but we used a standardized imaging protocol for all
subjects at all time points and radiographs were scored by a cali-
brated examiner with no knowledge of the genetics.
In conclusion, in this single study of limited sample size, we
found that commonly occurring IL1RN haplotypes were associ-
ated with radiographic progression of knee OA in a population
cohort of Caucasians. The predominant haplotypes that differ-
entiated risk could be efﬁciently tagged by three SNPs (rs419598,
rs9005, rs315943); and a conditional haplotype analysis indicates
that of the 12 IL1RN SNPs assayed, ﬁve SNPs (rs4251961,
rs380092, rs315952, rs315943, rs11374281) in two distinct LD
blocks are required for the observed haplotype association with
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